Gilead Sciences Inc. (GILD)
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment regimens. The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a centerpiece of the company's long-term strategy for HIV treatment and prevention.
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter. On the other hand, Livdelzi, a PPARδ agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Gilead Sciences Q2 Earnings Call Highlights
Gilead Sciences NASDAQ: GILD reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and increased its expected HIV growth rate, while reporting a quarterly non-GAAP loss driven by acquisition-related research and development charges.
